-
Rapport Therapeutics shares post hoc analysis of RAP-219 seizure drug
-
Citizens JMP Reiterates Market Outperform Rating on Rapport Therapeutics (RAPP)
-
Citizens JMP Reiterates Market Outperform Rating on Abivax (ABVX)
-
Truist Securities Starts Rapport Therapeutics (RAPP) at Buy
-
Rapport Therapeutics (RAPP) PT Raised to $34 at H.C. Wainwright
-
Rapport Therapeutics terminates stock sales agreement prospectus
-
Rapport Therapeutics (RAPP) PT Raised to $56 at Stifel
-
Rapport Therapeutics (RAPP) PT Raised to $77 at Citizens JMP
-
TD Cowen: 'Rapport Therapeutics (RAPP) Remains a Top Pick'
-
Citizens JMP Reiterates Market Outperform Rating on Rapport Therapeutics (RAPP)
-
Citizens JMP Reiterates Market Outperform Rating on Rapport Therapeutics (RAPP)
-
Rapport Therapeutics (RAPP) Files $400M Mixed Shelf
-
TD Cowen on Rapport Therapeutics (RAPP): 'KOL at Investor Dinner Strongly Optimistic for RAP-219'
-
Jones Trading Reiterates Buy Rating on Rapport Therapeutics (RAPP)
-
Stifel Reiterates Buy Rating on Rapport Therapeutics (RAPP)
-
Stifel Reiterates Buy Rating on Rapport Therapeutics (RAPP)
-
Citizens JMP Reiterates Market Outperform Rating on Rapport Therapeutics (RAPP)
-
Rapport Therapeutics, Inc. (RAPP) Reports Q1 Loss of $0.68
-
Citizens JMP Starts Rapport Therapeutics (RAPP) at Market Outperform, pt $28
-
Rapport Therapeutics (RAPP) Appoints Jeffrey Sevigny as Chief Medical Officer
-
TD Cowen: '10 Potential "Thome Run" Catalysts to Watch in 2025'
-
Jones Trading Starts Rapport Therapeutics (RAPP) at Buy
-
Stifel Reiterates Buy Rating on Rapport Therapeutics (RAPP)
-
TD Cowen Starts Rapport Therapeutics (RAPP) at Buy
-
Stifel Starts Rapport Therapeutics (RAPP) at Buy
-
Jefferies Starts Rapport Therapeutics (RAPP) at Buy

